Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3).

Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Abraham, George M; Jokela, Janet A; Forciea, Mary Ann; Miller, Matthew C; Humphrey, Linda L

Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Abraham, George M; Jokela, Janet A; Forciea, Mary Ann; Miller, Matthew C; Humphrey, Linda L.

Afiliación

Qaseem A; American College of Physicians, Philadelphia, Pennsylvania.
Yost J; American College of Physicians, Philadelphia, Pennsylvania, and Villanova University, Villanova, Pennsylvania.
Etxeandia-Ikobaltzeta I; American College of Physicians, Philadelphia, Pennsylvania.
Abraham GM; University of Massachusetts Medical School and Saint Vincent Hospital, Worcester, Massachusetts.
Jokela JA; University of Illinois College of Medicine at Urbana-Champaign, Champaign, Illinois.
Forciea MA; Penn Medicine, Philadelphia, Pennsylvania.
Miller MC; Penn Medicine, Philadelphia, Pennsylvania.
Humphrey LL; Portland Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon.

Ann Intern Med ; 175(5): W55-W57, 2022 05.

Article en En | MEDLINE | ID: mdl-35226518

Asunto(s)

Tratamiento Farmacológico de COVID-19; Médicos; Adenosina Monofosfato/análogos & derivados; Adenosina Monofosfato/uso terapéutico; Alanina/análogos & derivados; Antivirales/efectos adversos; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Médicos / Tratamiento Farmacológico de COVID-19 Límite: Humans Idioma: En Revista: Ann Intern Med Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google